Jena, Germany, May 3, 2018—InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company developing innovative therapeutics to treat inflammatory diseases by targeting the complement system, a key component of the innate immune system, announced today the pricing of its primary and secondary public offering of 3,000,000 common shares of the Company, consisting of 1,500,000 common shares offered by the Company and 1,500,000 common shares offered by the selling shareholders at price to the public of $34.00 per common share for total gross proceeds of approximately $102 million, consisting of total gross proceeds to the Company of approximately $51 million and total gross proceeds to the selling shareholders of approximately $51 million. In addition, InflaRx and the selling shareholders have granted the underwriters a 30-day option to purchase up to an additional 450,000 common shares at the public offering price, less underwriting discounts and commissions.
The offering is expected to close on or about May 8, 2018, subject to customary closing conditions.
J.P. Morgan, Leerink Partners and BMO Capital Markets are serving as joint book-running managers for the offering, with SunTrust Robinson Humphrey serving as lead manager.
InflaRx intends to use the net proceeds of the offering, together with cash and cash equivalents on hand, to conduct a Phase IIb clinical trial for IFX-1 in HS patients and a Phase II clinical development program for IFX-1 in AAV patients as well as to fund first clinical Phase II development in two additional neutrophil-driven indications within the autoimmune and inflammatory disease area and the remainder to fund other research and development activities, including the development of a subcutaneous administration of IFX-1 for the treatment of HS and exploratory development of IFX-1 in oncology, as well as for working capital and other general corporate purposes.
A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on May 3, 2018. The offering is being made only by means of a prospectus, copies of which may be obtained from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at (866) 803-9204; Leerink Partners LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, by telephone at (800) 808-7525, ext. 6132 or by email at firstname.lastname@example.org; or BMO Capital Markets Corp., Attention: Equity Syndicate Department, 3 Times Square, New York, NY 10036, by telephone at (800) 414-3627, or by email at email@example.com.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About InflaRx N.V.:
InflaRx (Nasdaq:IFRX) is a clinical-stage biopharmaceutical company focused on applying its proprietary anti-C5a technology to discover and develop first-in-class, potent and specific inhibitors of C5a. Complement C5a is a powerful inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. InflaRx was founded in 2007 and has offices in Jena and Munich, Germany. InflaRx is listed on the Nasdaq Global Select Market in the United States under the trading symbol “IFRX”.
Prof. Dr. Niels C. Riedemann - CEO
This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “estimate,” “believe,” “estimate,” “predict,” “potential” or “continue” and similar expressions. Forward-looking statements appear in a number of places throughout this release and may include statements regarding our intentions, beliefs, projections, outlook, analyses and current expectations concerning, among other things, whether we and our shareholders will close the offering of common shares, the anticipated use of proceeds from any funds raised from the offering, and the potential of our product candidates. Factors that may cause our actual results to differ from those expressed or implied in the forward-looking statements in this press release include, our ongoing and planned preclinical development and clinical trials, the timing of and our ability to make regulatory filings and obtain and maintain regulatory approvals for our product candidates, our intellectual property position, our ability to develop commercial functions, expectations regarding clinical trial data, our results of operations, cash needs, financial condition, liquidity, prospects, future transactions, growth and strategies, the industry in which we operate, the trends that may affect the industry or us and the risks uncertainties and other factors described under the heading “Risk Factors” in the preliminary prospectus filed with the Securities and Exchange Commission, InflaRx’s Annual Report on Form 20-F filed with the Securities and Exchange Commission on March 28, 2018, and the risks described in other filings that InflaRx may make with the Securities and Exchange Commission. These statements speak only as of the date of this press release and involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future, except as required by law.